Group One Trading, L.P. Purple Biotech Ltd. Transaction History

Group One Trading, L.P.

$3.01 Billion
Q2 2024

A detailed history of Group One Trading, L.P. transactions in Purple Biotech Ltd. stock. As of the latest transaction made, Group One Trading, L.P. holds 400 shares of PPBT stock, worth $2,160. This represents 0.0% of its overall portfolio holdings.

Number of Shares

400

Previous 3,206 87.52%

Holding current value

$2,160

Previous $2,000 100.0%

% of portfolio

0.0%

Previous 0.0%

13 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 14, 2024	SELL	$0.41 - $0.86 $1,150 - $2,413	-2,806 Reduced 87.52%	400 $0
Q1 2024 May 10, 2024	SELL	$0.58 - $0.92 $102 - $161	-176 Reduced 5.2%	3,206 $2,000
Q3 2023 Nov 09, 2023	BUY	$1.02 - $1.49 $12 - $17	12 Added 0.36%	3,382 $4,000
Q2 2023 Aug 09, 2023	SELL	$1.38 - $2.05 $1 - $2	-1 Reduced 0.03%	3,370 $4,000
Q1 2023 May 12, 2023	SELL	$1.36 - $2.3 $1,128 - $1,908	-830 Reduced 19.76%	3,371 $6,000
Q4 2022 Feb 09, 2023	SELL	$1.38 - $2.22 $27,511 - $44,257	-19,936 Reduced 82.6%	4,201 $5,000
Q3 2022 Nov 09, 2022	SELL	$1.9 - $2.69 $5,510 - $7,801	-2,900 Reduced 10.73%	24,137 $49,000
Q2 2022 Aug 11, 2022	BUY	$2.39 - $4.15 $2,390 - $4,150	1,000 Added 3.84%	27,037 $65,000
Q1 2022 May 12, 2022	BUY	$2.45 - $4.3 $43,994 - $77,215	17,957 Added 222.24%	26,037 $103,000
Q4 2021 Feb 11, 2022	SELL	$3.75 - $4.67 $145,496 - $181,191	-38,799 Reduced 82.76%	8,080 $31,000
Q3 2021 Nov 12, 2021	BUY	$4.4 - $5.59 $20,231 - $25,702	4,598 Added 10.87%	46,879 $214,000
Q2 2021 Aug 10, 2021	BUY	$3.75 - $6.72 $103,530 - $185,525	27,608 Added 188.16%	42,281 $206,000
Q1 2021 May 12, 2021	BUY	$3.93 - $6.99 $57,664 - $102,564	14,673 New	14,673 $61,000

Others Institutions Holding PPBT

# of Institutions

Shares Held

1.91M

Call Options Held

5.6K

Put Options Held

View Full List

About PURPLE BIOTECH LTD.

Ticker PPBT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 18,303,300
Market Cap $98.8M
Description
Purple Biotech Ltd., a clinical-stage company, focuses on developing therapies to overcome tumor immune evasion and drug for cancer patients in the United States. Its oncology pipeline includes CM24, a monoclonal antibody that blocks carcinoembryonic antigen related cell adhesion molecule 1 as a combination therapy with anti-PD-1 checkpoint inhi...

More about PPBT

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Group One Trading, L.P., based on Form 13F filings with the SEC.

News

Stay updated on Group One Trading, L.P. with notifications on news.

Account

Group One Trading, L.P. Purple Biotech Ltd. Transaction History